Research

Energy balance

Naltrexone, bupropion, or their combination (B-N) is not associated with the incidence of major cardiovascular adverse events (MACE) compared with placebo.

Clinicians can consider that these treatments do not increase the risk of major cardiovascular events.

StrongRefutesmedium confidence
Naltrexone, bupropion, or B‐N is not associated with the incidence of MACE as compared with placebo.
Andrei C. Spósito et al. · Obesity Reviews · 2021

Why this rating

Based on meta-analysis of 12 RCTs.

Source

Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta‐analyses

Andrei C. Spósito et al. · Obesity Reviews · 2021

DOI 10.1111/obr.13224

Meta-analysisCited 32×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →